Diversey Australia and New Zealand has announced its Oxivir Five 16 and Virex II ranges have been approved by the Therapeutic Goods Administration (TGA) with the label claim ‘Kills SARS-CoV-2 (COVID-19 virus)’.

This new claim is in addition to the current comprehensive list of claims under ARTG 286618 for Oxivir Five 16 and ARTG 153031 for Virex II.

“We are pleased to announce our Oxivir Five 16 and Virex II ranges have now gained TGA approval for a claim to kill COVID-19,” Wayne Hill, managing director, Diversey ANZ, said.

“This added claim offers confidence to our valued customers during this uncertain time. As a global company, Diversey continues to work tirelessly in product development, sourcing and testing to assist in controlling the spread of COVID-19.”

Oxivir Five 16 is an Accelerated Hydrogen Peroxide (AHP) based hospital grade cleaner disinfectant effective against a wide variety of pathogenic micro-organisms including viruses, bacteria, antibiotic-resistant bacteria, fungi, mould and mildew.

According to the company, Oxivir Five 16 kills pathogens including VRE, MRSA, Klebsiella, Acinetobacter, Pseudomonas, E.coli, Norovirus, Hepatitis B, Influenza A, RSV, Human Coronavirus 229E.

Virex II is low odour quaternary based hospital grade disinfectant cleaner that provides broad spectrum germicidal activity and kills SARS-CoV-2 (COVID-19 virus), HIV-1, HBV, VRE, MRSA, Avian Influenza Type A, Human Coronavirus 229E, controls mould and mildew and more.

Debbie Walker, marketing manager, Diversey ANZ, said as COVID-19 grow, the demand and urgency for cleaning and disinfection requirements has reached unprecedented levels.

“It was important we worked with the Australian TGA to add the COVID-19 claim to our Oxivir Tb, Oxivir Five 16 and Virex II range of products. It was also important we communicate this information to our valued customers.

“Whilst we celebrate this announcement, our stock level challenges persist due to unprecedented demands. We ask for patience as we service multiple essential services including healthcare and aged care facilities.”

The accreditation follows Diversey ANZ’s recent announcement that its OxivirTb has also received TGA approval for a COVID-19 label claim.

Comment below to have your say on this story.

If you have a news story or tip-off, get in touch at info@3.106.117.80. 

Sign up to INCLEAN’s newsletter.